HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.

Abstract
This study provides up-to-date and detailed cancer survival estimates of German patients with non-Hodgkin lymphoma (NHL, International Statistical Classification of Diseases 10th Revision [ICD-10] codes C82-C85) based on data from 11 cancer registries. Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology. Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period. Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1%. Survival decreased with age from 81.7% at age 15-49 to 46.5% at age 75+. Survival in the US was 75.3% at age 15-49 and 52% at age 75+. Survival was higher for women than for men, at 65.2% for women and 60.7% for men. Survivals for diffuse B-cell lymphoma and follicular lymphoma, the two most common subtypes of NHL, were 57.3% and 77.5%, respectively. Between 2002 and 2006, overall 5-year relative survival increased by 5.3 percentage points. We conclude that survival for NHL is increasing in Germany in recent years. Survival was higher in Germany than in the US for patients aged 15-49 but lower for older patients.
AuthorsDianne Pulte, Lina Jansen, Adam Gondos, Katharina Emrich, Bernd Holleczek, Alexander Katalinic, Hermann Brenner, GEKID Cancer Survival Working Group
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 54 Issue 5 Pg. 979-85 (May 2013) ISSN: 1029-2403 [Electronic] United States
PMID23098058 (Publication Type: Historical Article, Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Germany (epidemiology)
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Lymphoma, Non-Hodgkin (epidemiology, history, mortality)
  • Male
  • Middle Aged
  • Registries
  • SEER Program
  • United States (epidemiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: